Hosgood Sarah A, Yates Phillip J, Nicholson Michael L
Sarah A Hosgood, Phillip J Yates, Michael L Nicholson, Department of Infection, Immunity and Inflammation, Transplant Group, University of Leicester, LE5 4PW Leicester, United Kingdom.
World J Transplant. 2014 Dec 24;4(4):299-305. doi: 10.5500/wjt.v4.i4.299.
To investigate the effects of 1400W-a selective inducible nitric oxide synthase (iNOS) inhibitor in a model of donation after circulatory death (DCD) kidneys.
Porcine kidneys were retrieved after 25 min warm ischemia. They were then stored on ice for 18 h before being reperfused ex vivo with oxygenated autologous blood on an isolated organ perfusion system. The selective iNOS inhibitor 1400W (10 mg/kg) was administered before reperfusion (n = 6) vs control group (n = 7). Creatinine (1000 μmol/L) was added to the system, renal and tubular cell function and the level of ischemia reperfusion injury were assessed over 3 h of reperfusion using plasma, urine and tissue samples.
Kidneys treated with 1400W had a higher level of creatinine clearance (CrCl) [area under the curve (AUC) CrCl: 2.37 ± 0.97 mL/min per 100 g vs 0.96 ± 0.32 mL/min per 100 g, P = 0.004] and urine output [Total: 320 ± 96 mL vs 156 ± 82 mL, P = 0.008]. There was no significant difference in levels of fractional excretion of sodium (AUC, Fr ex Na+: Control, 186.3% ± 81.7%.h vs 1400W, 153.4% ± 12.1%.h, P = 0.429). Levels of total protein creatinine ratio were significantly lower in the 1400W group after 1 h of reperfusion (1h Pr/Cr: 1400W 9068 ± 6910 mg/L/mmol/L vs Control 21586 ± 5464 mg/L/mmol/L, P = 0.026). Levels of 8-isoprostane were significantly lower in the 1400W group [8-iso/creatinine ratio: Control 239 ± 136 pg/L/mmol/L vs 1400W 139 ± 47 pg/L/mmol/L, P = 0.041].
This study demonstrated that 1400W reduced ischaemia reperfusion injury in this porcine kidney model of DCD donor. Kidneys had improved renal function and reduced oxidative stress.
研究1400W(一种选择性诱导型一氧化氮合酶(iNOS)抑制剂)在心脏死亡后捐献(DCD)肾脏模型中的作用。
猪肾脏在经历25分钟热缺血后取出。然后将其置于冰上保存18小时,之后在离体器官灌注系统中用氧合自体血进行再灌注。在再灌注前给予选择性iNOS抑制剂1400W(10mg/kg)(n = 6),设对照组(n = 7)。向系统中加入肌酐(1000μmol/L),使用血浆、尿液和组织样本在再灌注3小时期间评估肾脏和肾小管细胞功能以及缺血再灌注损伤水平。
用1400W处理的肾脏肌酐清除率(CrCl)水平更高[曲线下面积(AUC)CrCl:2.37±0.97mL/(min·100g)vs 0.96±0.32mL/(min·100g),P = 0.004],尿量也更多[总量:320±96mL vs 156±82mL,P = 0.008]。钠排泄分数水平无显著差异(AUC,Fr ex Na +:对照组,186.3%±81.7%·h vs 1400W组,153.4%±12.1%·h,P = 0.429)。再灌注1小时后,1400W组的总蛋白肌酐比值水平显著更低(1小时Pr/Cr:1400W组9068±6910mg/L/mmol/L vs对照组21586±5464mg/L/mmol/L,P = 0.026)。1400W组的8-异前列腺素水平显著更低[8-异前列腺素/肌酐比值:对照组239±136pg/L/mmol/L vs 1400W组139±47pg/L/mmol/L,P = 0.041]。
本研究表明,在该DCD供体猪肾脏模型中,1400W可减轻缺血再灌注损伤。肾脏的肾功能得到改善,氧化应激减轻。